Valuation: PTC Therapeutics, Inc.

Market Cap 547.92Cr 474.61Cr 448.79Cr 406.3Cr 762.56Cr 53TCr 768.29Cr 5.36TCr 2.06TCr 27TCr 2.06TCr 2.01TCr 85TCr P/E 2026 *
42.2x
P/E 2027 * 23.9x
Enterprise Value 360.81Cr 312.53Cr 295.53Cr 267.55Cr 502.15Cr 35TCr 505.93Cr 3.53TCr 1.36TCr 18TCr 1.36TCr 1.33TCr 56TCr EV / Sales 2026 *
2.87x
EV / Sales 2027 * 2.42x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 547.92Cr
-0.19%+1.09%+51.85%+97.36% 1,01300Cr
+0.33%-0.71%+50.62%+65.50% 64TCr
+0.49%+5.73%+20.88%+72.92% 46TCr
-0.22%+2.88%+38.48%+37.98% 35TCr
-0.07%+1.82%+16.57%+23.39% 26TCr
-0.31%+2.02%+6.15%+10.75% 25TCr
-1.53%-4.46%+36.90%+44.08% 20TCr
-1.60%-5.51%-22.30%-58.60% 19TCr
+0.49%-0.23%+30.00%+93.34% 18TCr
Average -0.07%-1.08%+25.46%+42.97% 39.6TCr
Weighted average by Cap. +0.40%+0.01%+34.52%+59.42%

Financials

2026 *2027 *
Net sales 125.78Cr 108.95Cr 103.02Cr 93Cr 175.05Cr 12TCr 176.36Cr 1.23TCr 472.98Cr 6.12TCr 472.45Cr 461.98Cr 20TCr 137.6Cr 119.19Cr 112.71Cr 102.04Cr 191.51Cr 13TCr 192.95Cr 1.34TCr 517.45Cr 6.69TCr 516.88Cr 505.41Cr 21TCr
Net income 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 144.82Cr 56Cr 720.64Cr 56Cr 54Cr 2.3TCr 22Cr 19Cr 18Cr 16Cr 31Cr 2.13TCr 31Cr 216.87Cr 83Cr 1.08TCr 83Cr 81Cr 3.44TCr
Net Debt -187.11Cr -162.08Cr -153.26Cr -138.75Cr -260.41Cr -18TCr -262.37Cr -1.83TCr -703.63Cr -9.1TCr -702.85Cr -687.26Cr -29TCr -214.54Cr -185.83Cr -175.72Cr -159.09Cr -298.58Cr -21TCr -300.83Cr -2.1TCr -806.78Cr -10TCr -805.87Cr -788Cr -33TCr
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
65.65USD
Average target price
101.29USD
Spread / Average Target
+54.28%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!